Form 4: Gossamer Bio CCO Receives Equity Awards

Gossamer Bio's Chief Commercial Officer, Robert Paul Smith JR, was granted 93,750 restricted stock units and 562,500 stock options on January 2, 2026.

Summary

• Robert Paul Smith JR, Chief Commercial Officer of Gossamer Bio, Inc. (GOSS), reported new equity awards.
• Acquired 93,750 shares of Common Stock as a restricted stock unit (RSU) award, with a price of $0.
• These RSUs will vest in four equal annual installments, contingent on continuous service to the Issuer on each vesting date.
• Acquired 562,500 stock options with an exercise price of $2.88 per share, with a price of $0.
• The stock options will vest 25% on January 2, 2027, and 1/48th of the total number of shares subject to the option will vest on the last day of each one-month period thereafter, contingent on continuous service.
• The stock options have an expiration date of January 1, 2036.
• Following these transactions, Smith directly owns 260,898 shares of Common Stock and 562,500 stock options.
• An additional 25,000 shares of Common Stock are indirectly owned by a family trust.

Sentiment

Score: 7

Explanation: The filing indicates standard executive compensation practices, aligning management's interests with shareholders through equity awards. This is generally positive for corporate governance and long-term strategy, though it implies minor future dilution.

Positives

• The grant of restricted stock units and stock options aligns the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The multi-year vesting schedules for both the RSUs and stock options promote continuous service and commitment to the company's success over several years.

Negatives

• The issuance of new equity awards could lead to a minor dilutive effect on existing shareholders, although this is a standard practice for executive compensation.

Risks

• The value of the restricted stock units and stock options is subject to the future performance of Gossamer Bio's stock price. If the stock price declines, the value of these awards may decrease or become worthless.
• Vesting is contingent on continuous service, meaning the awards could be forfeited if the reporting person's employment terminates before vesting dates.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend several years into the future, indicating a long-term incentive structure for the Chief Commercial Officer. The RSUs vest in four equal annual installments, and the stock options vest 25% on January 2, 2027, with the remainder vesting monthly thereafter.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries, particularly for executive-level employees. This approach is widely used to attract, retain, and motivate key talent by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of equity awards, combining restricted stock units (RSUs) and stock options, is a common compensation strategy seen across the biotech sector, similar to practices at companies like Biogen or Gilead Sciences, which use a mix of time-based and performance-based equity to incentivize executives.
• The vesting schedule, with multi-year installments for RSUs and a multi-year schedule for options, is consistent with industry benchmarks designed to promote long-term retention and performance, often mirroring plans at peer companies such as Vertex Pharmaceuticals or Amgen.
• The exercise price of $2.88 for the stock options is typical for new grants, usually set at the market price on the grant date, reflecting standard compensation practices.

Stakeholder Impact

• Shareholders: Potential for minor future dilution from the vesting of RSUs and exercise of options, but also increased alignment of executive incentives with long-term shareholder value creation.
• Employees: Reflects standard executive compensation practices, which can set a precedent or expectation for other employees' incentive structures.

Next Steps

• The restricted stock units will vest in four equal annual installments, subject to continuous service.
• 25% of the stock options will vest on January 2, 2027, with 1/48th vesting monthly thereafter, subject to continuous service.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, insider transaction, equity award, restricted stock unit, RSU, stock option, executive compensation, Chief Commercial Officer, Robert Paul Smith JR